CLINICAL TRIALS PROFILE FOR PERFLUOROHEXYLOCTANE
✉ Email this page to a colleague
All Clinical Trials for perfluorohexyloctane
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00403702 ↗ | Comparison High-Density Silicone Oils in Retinal Detachment | Unknown status | Asociación para Evitar la Ceguera en México | Phase 2/Phase 3 | 2006-08-01 | The purpose of the study is to compare the safety, intraocular adverse effects and the anatomic and functional outcome with two endotamponade silicone oil after a 3-month in complex inferior retinal re-detachments. |
| NCT03333057 ↗ | Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) | Completed | Novaliq GmbH | Phase 2 | 2018-01-03 | This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED). |
| NCT04139798 ↗ | Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) | Completed | Bausch & Lomb Incorporated | Phase 3 | 2020-07-20 | This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD). |
| NCT04139798 ↗ | Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) | Completed | Novaliq GmbH | Phase 3 | 2020-07-20 | This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD). |
| NCT04140227 ↗ | Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) | Recruiting | Bausch & Lomb Incorporated | Phase 3 | 2020-09-24 | The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction). Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD. |
| NCT04140227 ↗ | Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) | Recruiting | Novaliq GmbH | Phase 3 | 2020-09-24 | The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction). Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for perfluorohexyloctane
Condition Name
Clinical Trial Locations for perfluorohexyloctane
Trials by Country
Clinical Trial Progress for perfluorohexyloctane
Clinical Trial Phase
Clinical Trial Sponsors for perfluorohexyloctane
Sponsor Name
